Type of the Paper (Article)

Molecular Insights of β-Lactamics Resistance *Klebsiella pneumoniae* Isolates with Focus on Multidrug Resistance and Virulence from Colonization Samples

Lavouisier F.B. Nogueira[#], Marília S. Maia[#], Marco A.F. Clementino[#], Ila F.N. Lima, Jorge L.N. Rodrigues, Luciana V.C. Fragoso, Glairta S. Costa, Jose Q.S. Filho, Alexandre Havt, Deiziane V.S. Costa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman, José K. Sousa* and Aldo A.M. Lima*

# - These authors contributed equally to this work.

* - Corresponding authors.

Abstract: *Klebsiella pneumoniae* is associated with high resistance to antimicrobials and is common in isolates from colonization and nosocomial infections. This study aims to develop assays to detect resistance genes belonging to the *bla* family and investigate metabolic pathways in resistant isolates of *K. pneumoniae*. The genes of the subfamilies included were: *bla*SHV, *bla*TEM, *bla*NDM, *bla*KPC, *bla*GES, *bla*CTX-M and relevant variants of the *bla*OXA subfamily. Mass spectrometry data were acquired on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Isolates from 122 *K. pneumoniae* samples were collected from 04/23/2019 to 05/29/2021. A high prevalence of resistance to penicillins, cephalosporins and carbapenems was found among the isolates. The identified genotypic profile showed a high prevalence of genes belonging to Ambler's classes of beta-lactamases A, B and D. In the metabolomic study, the N-fructosyl isoleucine metabolite was identified increased in multidrug-resistant (MDR) strains of *K. pneumoniae* compared to strains susceptible to antimicrobials. In

conclusion, the assays developed were efficient in detecting the main genes of the *bla* family of resistance in *K. pneumoniae*. The use of the pentose phosphate metabolic pathway suggests a benfical regulation of bacterial growt, and colonization in MDR *K. pneumoniae* strains, with may indicate the use of this pathway as a virulence mechanism in resistant strains.

KEYWORDS: Antimicrobial resistance; multidrug-resistant; β-lactamases; qPCR; molecular diagnosis; *Klebsiella pneumoniae*.

INTRODUCTION

Bacterial resistance to antimicrobial agents is a global public health problem that leads to an increase in the cost of treatment, length of stay, morbidity and mortality of hospitalized patients, especially in intensive care units (ICU).[1,2] In this sense, understanding the emergency mechanisms of regulation and dissemination of resistance to antimicrobial agents in the pathogenesis of bacterial colonization and/or infection can be of critical importance in preventing and controlling this problem.

Klebsiella pneumoniae is a Gram-negative γ-proteobacteria bacteria, belonging to the *Enterobacteriacae* family, and is generally viewed as an opportunistic microorganism, carrying several virulence factors and capable of accumulating resistance genes to various classes of antimicrobials. It is commonly related to cases of colonization and/or healthcare-associated infections (HAIs), and has been identified as an etiological agent in pneumonia, urinary tract infections (UTI), soft tissue and surgical wound infections, bacteremia, and sepsis.[3]

It is estimated that *K. pneumoniae* is responsible for approximately 10% of all cases of HAIs, and of these, 32.8% are caused by strains resistant to multiple

47 antimicrobial drugs. However, studies indicate that the rate of isolated strains
48 presenting resistance to antimicrobials has increased over the years.[4,5]

49 *K. pneumoniae* has been associated with the ability to overcome colonization
50 resistance imposed by the gastrointestinal microbiota[6] and has been reported as an
51 emerging Multidrug-Resistant microorgananism of emergency priority by the World
52 Health Organization (WHO) for the development of new therapies.[7] Epidemiological
53 data have demonstrated that *K. pneumoniae* can translocate from the gastrointestinal
54 tract to other sterile sites of the same host or other patients through the fecal-oral route.
55 What makes clear the clinical relevance of this microorganism. [8]

56 One of the most likely causes of the increasingly frequent emergence of
57 bacterial strains resistant to one or more antibiotics is the excessive and sometimes
58 incorrect use of antimicrobials. The relatively long time required to identify the
59 pathogen by traditional methods, as well as for the results of the antimicrobial
60 susceptibility test (AST), forces the clinician to use broad-spectrum drugs empirically,
61 increasing selective pressure, which ends up benefiting pathogens genetically capable
62 of adapting to the adverse environment.[1,9]

63 Possible answers to reduce the time needed to obtain a resistance profile, and to
64 investigate new approaches in treatment, is the development of molecular
65 methodologies, that can make the identification of resistance faster, and also be more
66 sensitive than the traditional methodologies.[10] And the investigation of metabolic
67 differences between sensitive and resistant strains, that can lead to metabolites or
68 pathways that can be used as targets for the development of new treatments and
69 strategies for dealing with multidrug-resistant (MDR) microorganisms. [11-12]

70 Beta-lactams are the class of antimicrobials most affected by resistance in
71 general, which is conferred in gram-negatives, mainly by the *bla* gene family, this
72 group of genes encodes enzymes called beta-lactamases, which are capable of
73 neutralizing the action of beta-lactams through hydrolysis of the beta-lactam ring.[13–15]

74 In this study it was investigated the phenotype of resistance, the genotypic
75 profile of the *bla* family of β-lactamases, and the metabolic differences between
76 sensitive and MDR *K. pneumoniae* strains, isolated from patients admitted to the ICU in
77 a university hospital in the city of Fortaleza-CE, Brazil.

78 We aim to develop a molecular assay, capable of identifying all variants of the
79 most relevant genes of the *bla* family, these being: *bla*SHV, *bla*TEM, *bla*NDM, *bla*KPC,
80 *bla*GES and *bla*CTX-M. In addition, also was included the most epidemiologically
81 relevant variants of the *bla*-OXA subfamily. Thus, creating a set of primers capable of
82 detecting the presence of hundreds of resistance genes with a reduced number of
83 reactions. Were also investigated the main differences between the metabolites up and
84 down regulated in sensitive and MDR strains of *K. pneumoniae*, both from the
85 intracellular medium and the supernatant among themselves and in comparison, with
86 the control medium.

87 **RESULTS**

88 **Selection of bacterial samples.** A total of 249 samples of Gram-negative
89 bacteria resistant to beta lactam antimicrobials were collected from 04/23/2019 to
90 05/29/2021, those were identified, and the most prevalent microorganism found was
91 *Klebsiella pneumoniae* 48.99% (122/249).

92 **Identification of the phenotypic profile of beta-lactams resistance of *K.***
93 ***pneumoniae* strains.** The bacteria isolates included in the study were tested against a
94 wide range of beta-lactams drugs, and the presence of a high percentage of isolates
95 resistant to these drugs was verified, which included **Penicillins**: ampicillin/sulbactam
96 (92.00%) and piperacillin/tazobactam (88.46%), **Cephalosporins**: cefepime (83.02%),
97 cefoxitin (73.68%), ceftazidime (86.54%), ceftazidime/avibactam (11 .76%), ceftriaxone
98 (83.02%), cefuroxime (90.38%) and cefuroxime axetil (81.82%) and **Carbapenems**:
99 ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%), as shown in **Figure**
100 **1**.



101

102 **Figure 1**. Prevalence of *K. pneumoniae* isolates resistant to the beta-lactams evaluated
103 (Penicillins, Cephalosporins and Carbapenems), demonstrating a phenotypic profile of
104 resistance to multiple beta-lactams drugs, in approximately 70% of the isolates, with
105 the exception of ceftazidime/avibactam and ertapenem.

106 **Primers design.** After selection on the platforms: Comprehensive Antibiotic
107 Resistance Data-base (CARD) and National Center for Biotecnology and Information
108 (NCBI, USA), and subsequent compilation and analysis of FASTA sequences, it was
109 possible to identify consensus sequences common to all sequences available in the
110 databases for each of the genes included in the study: *bla*SHV (N = 156), *bla*TEM (N =
111 167), *bla*NDM (N = 27), *bla*KPC (N = 208), *bla*GES (N = 25), and *bla*CTX-M (N = 144).
112 Except for the *blaOXA* gene, for which the most clinically relevant sequences were used
113 *(N = 203).*

114 The *bla*CTX-M and *bla*OXA genes, due to its diversity and high degree of
115 genetic variation between homologous sequences, were grouped into clades, and
116 divided into groups. the *bla*CTX-M gene group was named according to the
117 international standardization for this gene with the CTX-M 1*like* been divided into two
118 groups due to its high number or sequences and the genetic variation between them.
119 CTX-M 1.1*like* (N = 42), CTX-M 1.2*like* (N = 16), CTX-M 2*like* (N = 23), CTX-M 8*like* (N =
120 14) and CTX-M 9*like* (N = 49), while the *blaOXA* gene was divided into the OXA-*23like*
121 (N = 25), OXA-*24/40like* (N = 8), OXA-*48like* (N = 17) and OXA-*51like* (N = 153), as can
122 be seen in **Figures 2** and **3**.



Figure 2. Cladogram of the *bla*OXA subfamily showing the most epidemiologically relevant groups, covered by the primers developed, and the percentage of sequences identifiable by each primer in comparison with the total number of the *bla*OXA family (N = 441) at the time of publication of this work.



Figure 3. Cladogram with all sequences from the *bla*CTX-M subfamily divided into groups, illustrating the identifiable sequences, and the percentage of sequences detectable by each primer in comparison with the total number of the *bla*CTX-M family (N = 144) until the time of publication of this work.

A total of 14 pairs of primers were developed, which together have the capacity to detect 929 variants of resistance genes belonging to the *bla* gene family. The primer sequences for genes with conserved and non-conserved sequences can be found in **Tables 1** and **2**, respectively.

142 **Table 1.** Primer sequences for conserved genes

Name of gene	Number of variations detectable	Primer name	Sequence	Primer size
*bla*SHV	156	SHV-F	ATTATCTCCCTGTTAGCCACCC	22
		SHV-R	GTTTAATTTGCTCAAGCGGCTG	22
*bla*TEM	167	TEM-F	ACCCAGAAACGCTGGTGAAA	20
		TEM-R	GGGGCGAAAACTCTCAAGGA	20
*bla*NDM	27	NDM-F	GAAGCTGAGCACCGCATTAG	20
		NDM-R	CCATTTGCTGGCCAATCGTC	20
*bla*KPC	208	KPC-F	TCGCGGAACCATTCGCTAAA	20
		KPC-R	GAATGAGCTGCACAGTGGGA	20
*bla*GES	25	GES-F	GCCCAGGAGAGAGATTACGC	20
		GES-R	CTTGACCGACAGAGGCAACT	20

143

144

145 **Table 2.** Primer sequences for non-conserved genes, divided into clades.

	Name of gene	Number of variations detectable	Primer name	Sequence	Primer size
*bla*CTX-M	*bla*CTX-M 1.1*like*	42	CTXM1.1L-F	GATTGCGGAAAAGCACGTCA	20
			CTXM1.1L-R	TTCATCGCCACGTTATCGCT	20
	*bla*CTX-M 1.2*like*	16	CTXM1.2L-F	CGCCGCTGATTCTGGTCA	18
			CTXM1.2L-R	TGACGATTTTAGCCGCCGAC	20

	bla*CTX-M 2*like	23	CTXM2L-F	ATGGCGCAGACCCTGAAAAA	20
			CTXM2L-R	CTGCCGGTTTTATCGCCCA	19
	bla*CTX-M 8*like	14	CTXM8L-F	CGCTCAACACCGCGATCC	18
			CTXM8L-R	ATCCCCGACAACCCACGAT	19
	bla*CTX-M 9*like	49	CTXM9L-F	CGTGGCTCAAAGGCAATACG	20
			CTXM9L-R	TCTGTTGCGGCTGGGTAAAA	20
***bla*OXA**	***bla*OXA-23*like***	24	OXA23L-F	GCTCTAAGCCGCGCAAATAC	20
			OXA23L-R	TGACCTTTTCTCGCCCTTCC	20
	bla*OXA-24/40*like	8	OXA24/40L-F	TGCCGATGACCTTGCACATA	20
			OXA24/40L-R	CCATTAGCTTGCTCCACCCA	20
	bla*OXA-48*like	17	OXA48L-F	CGGTAGCAAAGGAATGGCAAG	21
			OXA48L-R	GGGCGATCAAGCTATTGGGA	20
	bla*OXA-51*like	153	OXA51L-F	GATCGGCCTTGAGCACCATA	20
			OXA51L-R	GCCATAACCAACACGCTTCA	20

***In silico* primers validation.** The parameters obtained for each primer after analysis using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite (SMS): PCR Primer Stats software are available in **Table 3**.

Table 3. Parameters obtained by *in silico* validation of the developed primers.

Gene	Primer name	Tm (C°)	GC%	Self complementarity	Self 3' complementarity	Produt length
***bla*SHV**	SHV-F	59,2	50,0	3	0	70
	SHV-R	59,3	45,4	5	3	
***bla*TEM**	TEM-F	60,1	50,0	4	0	110

	TEM-R	59,9	55,0	2	1	
***bla*NDM**	NDM-F	59,3	55,0	5	1	86
	NDM-R	60,1	55,0	6	2	
***bla*KPC**	KPC-F	60,3	50,0	4	2	128
	KPC-R	60,3	55,0	5	1	
***bla*GES**	GES-F	59,9	60,0	3	2	94
	GES-R	59,9	55,0	3	2	
bla*CTX-M 1.1*like	CTXM1.1L-F	59,7	50,0	4	1	87
	CTXM1.1L-R	60,1	50,0	4	2	
bla*CTX-M 1.2*like	CTXM1.2L-F	60,1	61,1	3	2	90
	CTXM1.2L-R	61,0	55,0	3	3	
bla*CTX-M 2*like	CTXM2L-F	60,5	50,0	4	0	155
	CTXM2L-R	60,7	57,8	4	1	
bla*CTX-M 8*like	CTXM8L-F	61,5	66,6	4	2	197
	CTXM8L-R	60,9	57,8	3	2	
bla*CTX-M 9*like	CTXM9L-F	59,9	55,0	3	2	180
	CTXM9L-R	60,1	50,0	3	0	
bla*OXA-23*like	OXA23L-F	60,0	55,0	4	0	129
	OXA23L-R	59,9	55,0	2	0	
bla*OXA-24/40*like	OXA24/40L-F	59,7	50,0	4	2	177
	OXA24/40L-R	60,0	55,0	4	0	
bla*OXA-48*like	OXA48L-F	59,8	52,3	3	0	183
	OXA48L-R	59,8	55,0	4	0	
bla*OXA-51*like	OXA51L-F	59,8	55,0	4	2	199
	OXA51L-R	59,1	50,0	2	1	

151

152 **Testing, optimization, and standardization of *in vitro* reactions.** All primers
153 were tested using positive controls developed *in house*, and it was possible to verify
154 that the ideal annealing temperature (Ta) for the developed primer pairs was 61°C,
155 except for the primer referring to the *bla*NDM gene, for which the ideal Ta was 64°C.
156 The reactions were then evaluated for their specificity and stability by checking the
157 Melting temperature (Tm). The melting curves are available in the supplementary
158 material **Figure S1**.

159 **Efficiency curve** It was found that all tested primers presented an efficiency
160 rate ≥93.21 and ≤101.28%, R^2 ≥0.99, and detection limit between ≈2 and ≈13 copies/μL as
161 shown in **Table 4**.

162 **Table 4.** Results of the efficiency curves of the developed primers.

Gene name	Efficiency (%)	Correlation coefficient (R^2)	Threshold	Detection limit (Copies/μL)	Melting Peak (Tm°C)
***bla*SHV**	96,15	0,992	0,60	≈2	86,7
***bla*TEM**	95,32	1,000	0,70	≈2	81,5
***bla*NDM**	99,90	0,999	0,48	≈2	85,7
***bla*KPC**	100,44	0,992	0,24	≈2	85,7
***bla*GES**	100,21	0,997	0,27	≈2	81,7
bla*CTX-M 1.1*like	95,75	0,999	0,40	≈13	84,3
bla*CTX-M 1.2*like	100,82	0,994	0,32	≈13	83,2
bla*CTX-M 2*like	98,09	0,998	0,30	≈2	86,4
bla*CTX-M 8*like	95,32	1,000	0,10	≈13	88,4
bla*CTX-M 9*like	97,82	0,996	0,10	≈2	89,0

bla*OXA-23*like	99,51	1,000	0,15	≈2	78,4
bla*OXA-24/40*like	101,82	0,988	0,15	≈13	78,7
bla*OXA-48*like	93,21	1,000	0,20	≈13	80,29
bla*OXA-51*like	95,51	0,993	0,55	≈2	82,0

Identification of the genetic resistance profile of *K. pneumoniae* isolates. The 122 *K. pneumoniae* isolates were tested against the 14 pairs of primers developed, and it was possible to verify a high prevalence of beta-lactam resistance genes among the isolates analyzed. The most prevalent genes detected were, respectively: *bla*KPC (95.90%); *bla*SHV (94.26%); *bla*CTX-M 1.2*like* (88.52%); *bla*CTX-M 2*like* (83.61%); *bla*CTX-M 1.1*like* (80.33%); *bla*TEM (80.33%); *bla*NDM (33.61%); *bla*OXA-23*like* (28.69%); *bla*GES (20.49%); *bla*OXA-51*like* (15.57%); *bla*CTX-M 9*like* (13.93%); *bla*CTX-M 8*like* (12.30%); *bla*OXA-24/40*like* (11.48%) *and bla*OXA-48*like* (3.28%). The results can be seen in **Figure 4A**, grouped according to Ambler's classification.

It is important to note that not all variants of each group of genes analyzed belong to a single class in the Ambler's classification, such as *bla*TEM and *bla*SHV genes, where not all variants have activity as extended spectrum beta-lactamases (ESBL) for example, however, due to the grouping of all sequences in a single primer, the separation of these sequences into other groups would be impossible, so the grouping of genes was carried out globally in a way that covered the mains classification of the subfamily in question.

Through the data obtained by the qPCR reactions developed, it was also possible to verify that the isolates analyzed during this study had the presence of

182 several genes belonging to the *bla* family accumulated, with values varying from 3 to

183 12 of the tested genes, present per isolate, as shown in **Figure 4B**.



184

185 **Figure 4**. **(A)** Prevalence of beta-lactams resistance genes among the analyzed isolates,

186 grouped according to the Ambler classification. **(B)** The percentage of *K. pneumoniae*

187 isolates showing accumulation of genes encoding beta-lactamases belonging to the *bla*

188 family.

189 **Comparisons of metabolomic profiles of *K. pneumoniae* isolates.** In total, 241
190 metabolites were identified in positive mode and 116 metabolites identified in negative
191 mode. Among these, 309 metabolites were identified by combining data from both
192 acquisition modes (positive and negative) without redundancy. The principal
193 component analysis (PCAs) and the heatmap analysis between the metabolites in
194 supernatant of susceptible *K. pneumoniae* versus the control culture medium showed
195 complete separation of the main vectors of the PCA plots and differential upregulation
196 or downregulation between the two experimental groups (**Figure 5**). Among these
197 metabolites, 25 were upregulated or downregulated. Interestingly, metabolites related
198 to the synthesis of nitrogenous bases, protein synthesis and energy supply to the
199 bacterial cell are significantly increased in supernatant derived from susceptible *K.*
200 *pneumoniae* (**Figures S2, S3 and S4**). Similar findings were detected between MDR *K.*
201 *pneumoniae* strains and control culture medium (**Figures S5, S6 and S7**).



Figure 5. Comparison between susceptible *K. pneumoniae* supernatants (Sens) versus culture media. **(A)** Plot of the principal component analysis (PCAs) and **(B)** the heatmap of the comparison of metabolites between the supernatant of susceptible *K. pneumoniae* versus the control culture media.

The principal component analysis (PCAs) and the heatmap analysis of metabolites in supernatants from *K. pneumoniae* MDR versus susceptible isolates exhibited complete separation of the main vectors of the PCA plots (**Figure 6A**) and differences on levels of metabolites (**Figure 6B**). The analysis of deregulated metabolites between *K. pneumoniae* MDR versus susceptible isolates showed increased N-fructosyl isoleucine in the MDR *K. pneumoniae* isolates ($p < 0.05$, **Figure 6C**).



Figure 6. Comparison of supernatants from *K. pneumoniae* MDR versus susceptible (Sens). **(A)** Plots of the principal component analysis (PCAs) and **(B)** the heatmap of the comparison of metabolites between the supernatant of *K. pneumoniae* MDR versus

susceptible (Sens). **(C)** Plots of dysregulated metabolites between supernatants of *K. pneumoniae* MDR and susceptible.

Analysis of the intracellular metabolites of susceptible versus MDR K. pneumoniae showed differences in the PCAs vectors (**Figure 7A**), heatmap (**Figure 7B**). and increased N-fructosyl isoleucine levels in the MDR K. pneumoniae isolates ($p<0.05$, **Figure 7C**). **Figure 8** shows the PCAs and heatmap plots of supernatant from sensitive and MDR K. pneumoniae.



Figure 7. Comparison of Intracellular media of *K. pneumoniae* MDR versus susceptible (Sens). **(A)** Principal Component Analysis (PCAs) plots and **(B)** Heatmap of the Intracellular Environment of *K. pneumoniae* MDR and susceptible. **(C)** Plots of dysregulated metabolites between the intracellular media of *K. pneumoniae* MDR and susceptible.



Figure 8. Comparison of *K. pneumoniae* Multidrug-Resistant (MDR) supernatants versus culture media. (A) Principal component analysis (PCAs) plots and (B) Heatmap of the supernatant of *K. pneumoniae* susceptible and MDR. Observe the separation of the main vectors of the (PCAs) plots and details of the differences in the heatmap between the two experimental groups.

DISCUSSION

During the period analyzed in the study, 249 bacterial isolates resistant to two or more class of antimicrobials used in TSA were identified. Of these resistant isolates, 48.99% (122/249) belonged to the species *Klebsiella pneumoniae*, being this microorganism the most prevalent among those identified.

This data is consistent with what is seen in Egypt, where when evaluating 186 samples from Cairo hospitals, *K. pneumoniae* was found as the main gram-negative bacterial agent representing 40.9% (76/186) of the identified microorganisms, and

245 among these isolates obtained, a high prevalence of resistance to beta-lactams,
246 quinolones, and sulfonamides was identified (89.4%, 89.4% and 87.1%) respectively.[16]

247 The phenotypic profile of the *K. pneumoniae* isolates analyzed in the present
248 study demonstrated high levels of resistance to the beta-lactams drugs tested in all
249 classes evaluated (penicillins, cephalosporins and carbapenems). Although the
250 resistance profile of strains may vary depending on the test location and the conditions
251 to prevent spread, the resistance to beta-lactams among *Enterobacteriaceae* is known to
252 be high, as demonstrated in a study carried out in Brazil, with samples of human and
253 veterinary origin where 62.85% and 54.28% of *Enterobacteriaceae* isolated were resistant
254 to amoxicillin/clavulonate and cefazolin respectively.[17]

255 In studies carried out in Egypt, evaluating isolates of *K. pneumoniae* from food
256 sources, and in Tunisia and Iran evaluating isolates from hospital samples, the
257 presence of high resistance to beta-lactams can be verified for ampicillin/sulbactam
258 (93%), ceftazidime (95.5%), cefoxitin (95.5%), cefotaxime (93.2%),
259 amoxicillin/clavulonate (86.4%), ertapenem (90.9%) and temocillin (84.0%).[18, 19, 20]

260 Likewise, in a study carried out with 102 isolates obtained from two Portuguese
261 hospitals, the presence of resistance rates > 90% was verified for all beta-lactam drugs
262 tested, except for cephalosporins: cefoxitin (40.2%), cefotetan (68.6%) and carbapenems:
263 ertapenem (23.5%), imipenem (32.4%), meropenem (34.3%) and doripenem (33.3%).[21]

264 This result is consistent with that found in this study, where the beta-lactam
265 drugs that showed a lower resistance rate belonged to the same classes mentioned,
266 namely: cefoxitin (73.68%), ceftazidime/avibactam (11.76%), ertapenem (44.00%),
267 imipenem (71.70%) and meropenem (69.81%).

268 Resistance to beta-lactams is conferred in Gram-negatives mainly by genes
269 belonging to the *bla* family. This group of genes is composed of dozens of subfamilies
270 and hundreds of genetic subvariants in each family, the molecular panel developed
271 managed to encompass some of the most predominant and clinical relevant
272 subfamilies among clinical isolates, identified in several studies, namely: *bla*SHV,
273 *bla*TEM, *bla*NDM, *bla*KPC, *bla*GES, *bla*CTX-M and *bla*OXA.[22–24]

274 After analysis using the Primer-BLAST® (NCBI, USA) and Primer Stats
275 Sequence Manipulation Suite (SMS) software, it was verified that the developed
276 primers have specificity for the sequences used in the alignment, melting temperature
277 (Tm) between 59 29 °C and 61.55 °C, GC% concentration varying between 45.45% and
278 66.67% in addition to having complementary base numbers ≤ 6 in the analysis of dimer
279 and hairpin formation. The values obtained for these parameters therefore demonstrate
280 that they are compatible with those obtained in reference studies.[25–27]

281 Due to the high number of sequences included in the development of primers,
282 many of the alternatives obtained through Primer-BLAST® (NCBI, USA) did not meet
283 the stability requirements regarding the formation of secondary structures (self-
284 annealing and hairpins), In order to choose the options with the best performance in
285 relation to these parameters, the GC clamp was relaxed so that the primers SHV-F,
286 SHV-R, CTXM1.2L-R and CTXM2L-R obtained 4 G or C residues within the last 5
287 nucleotides of the 3' end, the primers CTXM9L-R and CTXM2L-F did not present C or
288 G residues within the last 5 nucleotides of the sequence.

289 This fact could lead to the formation of strong bonds and increase the Tm value
290 in primers with more than 3 terminal GC residues, and cause inhibition of
291 amplification due to the presence of weak bonds when there is an absence of terminal

292 CG [28,29]. Such changes, however, were not evident when the primers were tested *in*
293 *vitro*.

294 The variety of sequences detectable by the developed primers makes in vitro
295 validation using positive controls for all sequences virtually impossible. In silico
296 analysis allowed the evaluation of all tested sequences quickly, cheaply and constantly,
297 since the developed primers can be tested against new variants of the target genes.[26–28]

298 In vitro analyzes were carried out using SYBR Green master mix, the melting
299 curve was therefore used as a parameter to evaluate the specificity of the reactions.
300 And it was verified that for all tested primers a single melting peak was found,
301 indicating the formation of a single amplicon. And excluding the presence of
302 secondary structures (primer dimers and hairpins).

303 The analysis of the melting curve and Tm is considered fundamental to test the
304 specificity of reactions that use SYBR Green as an amplification indicator, because
305 unlike reactions that use specific probes, which emit fluorescence only when the
306 reaction occurs at the expected target. The SYBR Green works by binding to any
307 double-stranded fragment formed, thus emitting fluorescence. Therefore, only by
308 analyzing the melting curve and the specific Tm of the amplicon is it possible to
309 determine whether the reaction was successful.[29–31]

310 The efficiency curve and its parameters were used to evaluate the performance
311 of qPCR reactions, by checking how efficiently the targets were amplified in each PCR
312 cycle.[32, 33] When evaluating the activity of primers in qPCR reactions using the
313 efficiency curve, it was found that all primers analyzed in this study presented
314 efficiency values >90% and <110% and correlation coefficients (R^2) >0.9, thus being in
315 accordance with the parameters presented in reference documents present in the

316 literature.[33] It was also possible to verify a high detection capacity even at low
317 concentrations of genetic material since the detection limit obtained varied between ≈2
318 and ≈13 copies/μL of the target gene used as control.

319 Several studies report the growth in the prevalence of the *bla*KPC gene, with
320 this being the most detected carbapenemase worldwide. The values found vary
321 according to the location. The main variant of the *bla*KPC gene detected is *bla*KPC-2,
322 with prevalence values varying from 1.2% to 51.6% among enterobacteria in studies
323 carried out in the United States of America and China respectively.[34, 35] This gene is
324 found more frequently in isolates of *K. pneumoniae*, many studies report high
325 prevalence rates in this species ranging from 17.2% to 64.6%.[4, 35, 36, 37]

326 In a study conducted in an intensive care unit in the northeast reagion of Brazil,
327 it was shown that of 25 isoates of *K.* pneumoniae obtained during the research, 100%
328 exhibited the presence of the *bla*KPC gene. [38]

329 The values found in this paper for the *bla*KPC gene may reflect the fact that the
330 primer developed detected all variants of the gene, as well as the higher rates of
331 resistance usually found in intensive care unities (ICU).[39]

332 The results found in this work are in agreement with other studies performed at
333 the northeast of Brazil[38], what can represent an endemic presence of the *bla*KPC gene
334 among *K. pneumoniae* isolates in this Brazilian region.

335 The *bla*TEM and *bla*SHV genes were the first ESBL identified, and together with
336 the *bla*CTX-M subfamily of genes are considered the most prevalent ESBL's. These
337 genes are widely distributed among enterobacteria; in a study carried out in Sudan, the
338 *bla*TEM, *bla*CTX-M and *bla*SHV genes were identified in 86.0%, 78.0% and 28.0%
339 respectively.[40]

340 In a work carried out in ICUs in Chile, it was possible to verify the presence of
341 these genes with prevalence rates of 81.0%, 84.7% and 73.0% for *bla*SHV, *bla*CTX-M-1
342 and *bla*TEM, where a higher prevalence of the *bla*SHV gene was found when compared
343 to the study carried out in Sudan.[41]

344 In Brazil, it is also possible to verify the presence of high prevalence rates of
345 these genes among *K.* pneumoniae isolates from ICU, with studies indicating rates of
346 100%, 96% and 72% for *bla*TEM, *bla*SHV and *bla*CTX-M1 respectively. [38] These results
347 agree with those evidenced in this study for the K. pneumoniae isolates tested.

348 The *bla*NDM gene is considered the second most prevalent carbapenemase
349 producing gene in the world, behind only the *bla*KPC gene. In this study, the presence
350 of the metallo beta-lactamase NDM gene was verified in (33.61%) of the isolates.
351 Similar results were evidenced in China, where the presence of this gene was verified
352 in 35.7% of 935 carbapenem-resistant enterobacteria tested.[34]

353 The prevalence found in this study for the *bla*NDM gene is still below what was
354 found in other studies carried out in Brazil in the states of São Paulo and Sergipe,
355 where the authors found a prevalence of 70 and 50% respectively in *K. pneumoniae*
356 isolates. [42, 43]

357 Regarding oxacillinases, a low prevalence of the *bla*OXA-48*like* gene was
358 observed (3.28%). This gene may be present in all *Enterobacteriaceae*; however, it is more
359 prevalent in strains of *K. pneumoniae*.[21]

360 The values found in the literature for the presence of this gene in
361 *Enterobacteriaceae* are very divergent, with marked variations related to the location of
362 the analysis, these values vary from 7.3% in China to 83.3% in Morocco.[34, 44] In a study
363 conducted in Brazil where 4,451 isolates of *Enterobacteriaceae* were analyzed, the

364 *bla*OXA-48*like* gene was detected in only 2.5% of the isolates tested.[45] In this way, the
365 result obtained is compatible with what was previously identified in Brazil, and close
366 to what is seen in China.

367 The presence of variants of the *bla*OXA gene (*bla*-OXA-51*like* (15.57%), *bla*OXA-
368 24/40*like* (11.48%) and *bla*OXA-23*like* (28.69%)) was also observed in the isolates tested,
369 these genes were long considered exclusive to strains of *Acinetobacter baumannii*,
370 however studies have demonstrated the presence of these genes in other
371 *Enterobacteriaceae*, including *K. pneumoniae*.[46] Results regarding the prevalence of these
372 genes in strains of *K. pneumoniae* are still scarce, however, in a study conducted in
373 Bahrain in the Persian Gulf, the *bla*OXA-*51* and *bla*OXA-*23* genes were identified
374 respectively in 45.8% and 41.6%. % of *K. pneumoniae* isolates analyzed.[47]

375 It is believed that many of the beta-lactamases that today can be found
376 contained in mobile genetic elements had their origin in chromosomes of other
377 bacteria, as occurred with the SHV type variants that derived from the *K. pneumoniae*
378 chromosomal SHV-1, and the CTX-M type variants that appear to have originated from
379 the chromosomal CTX-M of *Kluyvera* spp[21]. This change in the presentation of these
380 genes, from chromosomal to mobile elements, may explain the appearance of genes
381 such as chromosomal *bla*OXA present in *A. baumannii* strains on plasmids widespread
382 in other species.

383 It was possible to verify the presence of isolates presenting multiple genes
384 coding for beta-lactamases, from 3 to 12 of the genes analyzed. Studies point to a high
385 prevalence among *Enterobacteriaceae* of the accumulation of genes from the *bla* family,
386 mainly genes belonging to ESBL, OXA beta-lactamases and carbapenemases such as
387 *bla*KPC and *bla*NDM. This phenomenon is more evident in hospital environments

388 where selective pressure favors microorganisms carrying resistance genes and where
389 there is a high rate of sharing of these genes.[48,49]

390 Investigations into metabolomic modulation in *K. pneumoniae* have
391 demonstrated a promising area for understanding resistance to antimicrobial agents,
392 developing new therapies, and for studying bacterial virulence. For example,
393 significant inhibition of the pentose phosphate pathway, citrate cycle, amino acid and
394 nucleotide metabolism was observed to be beneficial during treatment of MDR *K.*
395 *pneumoniae* using the bacteriophage-polymyxin combination, showing the potential for
396 new therapeutic targets and pathways metabolic processes to improve the effectiveness
397 of treatment with available antimicrobial agents.[50,51]

398 This study is in accordance with others that highlighted the importance of the
399 pentose phosphate pathway in MDR *K. pneumoniae* strains.[50] This finding was present
400 in both media, supernatant and intracellular in MDR isolates, compared with *K.*
401 *pneumoniae* isolates susceptible to antimicrobial agents. The significant presence of the
402 metabolic N-fructosyl isoleucine ($C_{12}H_{23}NO_7$; MW: 293.316) in the supernatant and
403 intracellular media of *K. pneumoniae* MDR indicates the expression of the fructose
404 degradation enzyme gene (*frwC*; fructose-specific phosphotransferase system), which is
405 involved in regulating bacterial growth, virulence and overcoming colonization
406 resistance due to the use of alternative carbon source from fructose.[52, 53]

407 Metabolomics has proven to be a promising approach in the study of
408 antimicrobial resistance. Its use allows for the comprehensive investigation of
409 metabolic changes associates with different resistance mechanisms, such as alternative
410 energy-obtaining pathways, modifications that alter the cell wall, communication

411 between bacterial cells, and changes in the colonization capacity of these
412 microorganisms.[54, 55]

413 The identification of these metabolic differences plays an important role in the
414 Discovery of new therapeutic targets and strategies for investigating the reversal of
415 resistance in these pathogens.[55-57] The combination of genetic and metabolomic
416 techniques therefore contributes to a comprehensive view of resistance mechanisms in
417 bacteria. [56,57]

418 The presence of N-fructosyl isoleucine in resistant strains, and the metabolic
419 benefit that its presence appears to generate in increasing colonization capacity,
420 together with the selective pressure found in ICU environments due to the constant use
421 of antimicrobials may be related to the high rates of resistant isolates disseminated
422 among patients in this environment.

423 The metabolic evaluation in turn points to a metabolic advantage in resistant
424 strains compared to sensitive ones, which goes beyond the resistance capacity itself.[58]

425 This study has some limitations, such as the exploration of only *bla* family
426 genes, limiting a broader understanding of resistance mechanisms to antimicrobial
427 agents. On the other hand, it presents a broad methodology for exploring the
428 important *bla* family genes most associated with resistance to beta-lactams in *K.*
429 *pneumonia*. The metabolic findings showed a specific indication that suggests an
430 association with virulence and better proteomic studies will be necessary to associate
431 with potential mechanisms of resistance to antimicrobial agents. Furthermore,
432 additional preclinical studies will be necessary to determine and more specifically
433 validate the virulence associated with the pentose phosphate pathway in *K.*
434 *pneumoniae*.

435

436

437 **CONCLUSIONS**

438 The results of this work show the high prevalence of resistance to antimicrobial
439 agents in isolates of *K. pneumoniae* within the hospital environment, and that this
440 phenotypic pattern exhibited a great concern as it limits the therapeutic options
441 available, directly implicating the patient's prognosis.

442 The assays developed were within the quality criteria for qPCR reactions using
443 SYBR Green master mix and were efficient in detecting the beta-lactams resistance
444 genes from the *bla* family evaluated in this study. The genotypes of the *bla* genes
445 obtained are relevant and worrying for the local hospital scenario, and compatible with
446 the identified phenotypic profile.

447 The identification of the metabolic N-fructosyl isoleucine in the supernatant
448 and intracellular media of *K. pneumoniae* MDR indicates the expression of the fructose
449 degradation enzyme gene, which is involved in regulating bacterial growth, virulence
450 and overcoming resistance to colonization due to the use of an alternative carbon
451 source from fructose.

452 **MATERIALS AND METHODS**

453 **Obtaining bacterial isolates and identification.** For the following study,
454 samples were collected, as part of the clinical investigation of patients admitted to the
455 ICU of a tertiary care health unit in the city of Fortaleza-CE. Were included in the work
456 those microorganisms that were identified as gram-negative bacteria, resistant to two

457 or more groups of antimicrobial agents, including subclasses of β-lactams,
458 fluoroquinolones and aminoglycosides.

459 The bacterial isolates were identified and tested for their susceptibility to
460 antimicrobials using the automated VITEK® 2 Compact method (BioMérieux, Marcy
461 l'Etoile, France), according to the manufacturer's recommendations. Minimum
462 inhibitory concentrations were interpreted according to the Clinical and Laboratory
463 Standards Institute (CLSI). For quality control of sensitivity tests, strains from the
464 American Type Culture Collection (ATCC) were used. Specimens that had a resistance
465 profile that fit the research objectives were included in the study.

466 **Extraction of bacterial DNA.** To extract the genetic material, the Wizard
467 Genomic DNA Purification extraction and purification kit (Promega, Madison, USA)
468 was used, according to the manufacturer's recommendations.

469 After extraction, all samples were then quantified by spectrophotometry using
470 the NanoDropTM 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and
471 stored in a -80°C freezer until used in the experiments.

472 **Selection of genes used in the study and obtaining FASTA sequences.** For
473 greater coverage of the genetic profile of resistance to β-lactams in gram-negatives,
474 genes with relevant prevalence epidemiology, belonging to the *bla* gene family, were
475 part of the study, and these included the genes*: blaSHV, blaTEM, blaNDM, blaKPC,*
476 *blaGES, blaCTX-M and blaOXA*. The sequences used were obtained through the
477 Comprehensive Antibiotic Resistance Database (CARD) and National Center for
478 Biotecnology information (NCBI) platforms, which compiles and organizes the

479 resistance gene sequences available in GenBanck, the list of identifiable sequences is
480 available in the supplementary material Text S1.

481 **Primer design.** To design the primers, all variant sequences of each gene
482 included in the study available on the CARD and NCBI platforms were gathered, the
483 sequences were aligned using the Clustal Omega software, and the alignments were
484 analyzed using the SnapGene software.

485 Consensus regions with homology ≥95% were selected and these were used to
486 design the primers using the Primer Blast platform from the National Center for
487 Biotechnology and Information (NCBI, USA). The consensus sequences obtained is
488 available in the supplementary material Text S2.

489 Genes with few conserved regions, for which it was not possible to obtain
490 consensus sequences with homology ≥95%, were separated into clades, and primers
491 were then designed for the sequences by phylogenetic grouping, complying with a
492 minimum of 95% similarity.

493 ***In silico* validation of the developed primers.** All primers developed were
494 validated *in silico* regarding their specificity, structure, formation of primer-dimers and
495 hairpins using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite
496 (SMS): PCR Primer Stats platforms.

497 **Testing, optimization, and standardization of primers.** The reactions were
498 standardized with the use of positive controls developed in-house, through
499 amplification of genetic material, isolation, and purification of amplicons, originating
500 from isolates phenotypically resistant to beta-lactams, and negative control (water
501 DNase/RNase free). They were carried out using a CYBR Green master mix (Promega,

502 Madison, USA), the initial results were evaluated regarding the melting temperature
503 (Tm), to confirm the specificity of the amplicons.

504 To determine the most efficient qPCR conditions, to reduce the existence of
505 non-specificity and facilitate the interpretation of the results, the concentration gradient
506 and annealing temperature (Ta) of the primers were performed. The qPCR reaction
507 conditions included a hot start step at 95°C for 2 minutes, followed by 35 cycles
508 consisting of a denaturation step for 15 seconds at 95°C, and an annealing/extension
509 step for 1 minute at Ta. specific to each primer, all reactions went through a final
510 melting curve step, with a temperature variation of 60 to 95°C with an increase of
511 0.05°C/sec.

512 A 9-point efficiency curve was performed with a dilution factor of 1:8, for each
513 primer developed, with concentrations ranging from ≈27,438,596 to ≈2 (copies/μL),
514 through this procedure it was possible to determine the values of threshold, evaluate
515 the efficiency (%), the correlation coefficient (R^2) and the limit of detection of each
516 primer.

517 **Detection of resistance-related genes by molecular biology.** The *K. pneumoniae*
518 isolates obtained in the study were tested against the developed primers. Melting
519 curve analysis of all reactions was used to evaluate the specificity of the results of the
520 isolates in comparison to the specific melting temperature (Tm) of the positive control.

521 **Preparation of *K.* pneumoniae samples for metabolomic evaluation.** Isolates
522 of *K. pneumoniae* susceptible and multidrug resistant to antimicrobial agents obtained
523 in this work were submitted for metabolomic analysis. For this experiment, seven
524 samples of the culture supernatant were designed: one sample of the culture medium,
525 two samples of the culture supernatant of susceptible *K. pneumoniae* (biological

526 replicates), four samples of the culture supernatant of multidrug-resistant *K.*
527 *pneumoniae* (MDR) for untargeted metabolomics determination and analysis. Samples
528 of the intracellular medium of the *K. pneumoniae* culture, two samples of susceptible *K.*
529 *pneumoniae* (biological replicates) and four samples of MDR *K. pneumoniae* were also
530 used for untargeted metabolomic analysis. Technical replicates were performed for
531 susceptible media and samples to allow for a pilot statistical comparison.

532 **Methodology for extracting *K. pneumoniae* culture supernatant.** To 200 μL of
533 *K. pneumoniae* culture medium or control medium, 800 μL of 80% methanol was added
534 at -20 °C. The samples were vortexed and incubated at -20°C for 2 hours for protein
535 precipitation. The samples were centrifuged for 10 min at 4°C at 10,000 g (Benchtop
536 refrigerated centrifuge 10k RPM Eppendorf) and the supernatants were transferred to
537 new tubes. The samples were dried under vacuum (Speed Vac Thermo fisher) for
538 approximately 4-5 hours. Dried samples were redissolved in 100 μL of 0.1% formic
539 acid in water containing Metabolomics QReSS labeled heavy standards diluted 100X.
540 (https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). A
541 quality control (QC) was done, combining 10 μL of each sample. After the QC test in
542 the mass spectrometer, the samples were diluted 10x to be analyzed. The injection
543 volume of each sample was 10 μL per ionization mode.

544 **Methodology for extractions from the intracellular medium of *K. pneumoniae***
545 **culture.** To each tube, 750 μL of cold chloroform:methanol (2:1) mixture at -20 °C was
546 added, vortexed and transferred to tubes reinforced with a ball beater. Cells were
547 disrupted in a bead beater with steel balls for 3 min at an intensity of 5 (Bead Ruptor
548 Elite Omni International Material). The tubes were shaken vigorously for 30 min at 4°C
549 in a temperature-controlled thermal shaker (Thermomixer Eppendorf). 400 μL of water

550 was added, shaken vigorously, and centrifuged for 10 min at 10,000 rpm (Benchtop
551 refrigerated centrifuge 10k RPM Eppendorf) for phase separation. The upper
552 aqueous/methanolic phase was saved as a mixture of soluble metabolites and
553 transferred to Eppendorf tubes. Soluble metabolites were dried under vacuum for 3-4 h
554 (Speed Vac Thermo Fisher). Before running, samples were reconstituted in 100 μL of
555 0.1% formic acid in water containing 100X diluted Metabolomics QReSS labeled heavy
556 standards
557 (https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). The
558 QC sample was prepared with 10 μL of each sample. The injection volume of each
559 sample was 10 μL.

560 **Analysis by Ultra Performance Liquid Chromatography Coupled to Tandem**
561 **Mass Spectrometry (UPLC-MS/MS) of metabolites.** MS data were acquired on the
562 Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. Soluble
563 metabolites were separated using a Waters BEH C18 column (100 x 2.1 mm, 1.9 μm)
564 operated at 30 °C and a flow rate of 250 μL/min. Mobile phase A was 0.1% formic acid
565 in water and mobile phase B was 0.1% formic acid in 90% methanol. Bulk scan range:
566 67-1000 at 120,000 resolutions with 0.6 sec scan range. The 10 most intense ions in each
567 full scan were selected for fragmentation and MS2 spectra were acquired at a
568 resolution of 30,000 and scaled collision dissociation fragmentation energy of 25, 30, 35
569 was used.

570 **UPLC gradient.** The total time used in the UPLC gradient runs was 15 minutes.
571 The flow used was 0.250 mL/min and the following gradient in the percentage of
572 mobile phase B was 50% at 8 min, 98% at 9 min. maintaining until a time of 13 min.,
573 ending with 0% between a time of 13.1 – 15 min.

574 **Verification settings in the mass spectrum.** The configurations used in the
575 verification through the mass spectrum were orbit trap of the mass spectrum in the
576 master scan, with an orbitrap detector with a resolution of 120,000. We used
577 quadrupole isolation with a scanning range between 67-1000 m/z, using the frequency
578 lens at 60%. The automatic gain control target was customized and normalized to 25%.
579 The maximum injection time mode has been customized with a maximum injection
580 time of 50 ms. MIcroscans of 1 and profile with positive polarity. Font fragmentation
581 has been disabled.

582 **Data acquisition, metabolic identification, and data analysis.** Once the data
583 was acquired, the samples were analyzed using the open-source software MS-DIAL.
584 More details about the software can be obtained here:
585 http://prime.psc.riken.jp/compms/msdial/main.html.[59,60] Three blank samples were
586 included in the analysis to identify background ions and remove them later. Samples
587 acquired using MS1 full scan used for quantification and data-dependent acquisition
588 (DDA) mode were used for spectral identification of metabolites. Tolerance MS1 was
589 set to 0.01 Da and MS2 set to 0.025 Da. For peak harvesting, the mass slice width was
590 set to 0.1. For peak alignment, the maximum retention time tolerance was set at 0.5
591 min, the MS1 tolerance was set at 0.01. Peaks were identified by searching MS2 spectra
592 in the public MS-DIAL database downloaded in January 2023 (324,191 records for
593 positive mode and 64,669 entries for negative mode) using a mass tolerance of 0.01 Da
594 for MS1 and 0.05 Gives to MSMS with an identification cutoff point of 80%
595 http://prime.psc.riken.jp/compms/msdial/main.html#MSP. Additionally, peaks were
596 also searched against the core Biomolecular Analysis Facility's internal IROA library
597 (both positive and negative mode) with a mass tolerance of 0.02 and identification

598 cutoff of 85%. The data was manually inspected and identifications without MS2 were
599 filtered, except for identifications of the IROA molecule.
600
601
602
603 **Supplementary Materials**: The following supporting information: Figures S1-S7; Text
604 S1; Text S2.
605 **Figure supplement legend:**
606 **Figure S1** – Primer's specificity evaluation through Melting curve: (A) SHV, (B)
607 KPC, (C) NDM, (D) TEM, (E) GES, (F) OXA-23*like*, (G) OXA-24/40like, (H) OXA-48like,
608 (I) OXA-51like, (J) CTX-M 1.1*like*, (K) CTX-M 1.2*like*, (L) CTX-M 2*like*, (M) CTX-M 8*like* e
609 (N) CTX-M 9*like*.
610 **Figure S2** - Plot analysis of the 25 main metabolites from the supernatant of
611 susceptible *K. pneumoniae* in general without separation by up- or down-regulation of
612 the analytes. Note that in the supernatant of *K. pneumoniae* compared to the culture
613 media, metabolites related to the synthesis of nitrogenous bases, protein synthesis and
614 energy supply to the bacterial cell are significantly increased.
615 **Figure S3** - Plot of the analysis of the 25 main metabolites from the supernatant
616 of susceptible *K. pneumoniae*, separated because they were up-regulated in relation to
617 the control culture media.
618 **Figure S4** - Plot of the analysis of the 25 main metabolites from the supernatant
619 of susceptible *K. pneumoniae*, separated because they were down-regulated in relation
620 to the control culture media.

621 **Figure S5** - Plot of the analyzes of the 25 main metabolites from the supernatant
622 of Multidrug-Resistant (MDR) *K. pneumoniae* in general without separation by up- or
623 down-regulation in the analytes. Note that in the intracellular media of *K. pneumoniae*
624 compared to the culture medium, metabolites related to the synthesis of nitrogenous
625 bases, protein synthesis and energy supply to the bacterial cell are significantly
626 increased.

627 **Figure S6** - Plot of the analysis of the 25 main metabolites from the supernatant
628 of *K. pneumoniae* MDR, separated by being up-regulated in relation to the control
629 culture media.

630 **Figure S7** - Plot d of the analysis of the 25 main metabolites from the
631 supernatant of *K. pneumoniae* MDR, separated because they were down-regulated in
632 relation to the control culture media.

633

634 AUTHOR INFORMATION

635 **Corresponding Authors:**

636 **Aldo A.M. Lima - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,**
637 **Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department**
638 **of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.**
639 https://orcid.org/0000-0002-0299-1747

640 **Email**: alima@ufc.br

641 **José Kleybson de Sousa** – Department of Pediatrics Gastroenterology, UVA Hospital,
642 University of Virginia, Charlottesville, Virginia 22903, United States;
643 https://orcid.org/0000-0003-3512-484X

Email: ztx7ex@virginia.edu;

Authors

Lavouisier F.B. Nogueira - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-5008-8181

Marília S. Maia - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-7005-7841

Marco A.F Clementino - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-0628-8047

Ila F.N. Lima – Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

Jorge L.N. Rodrigues - Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

Luciana V.C. Fragoso - Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

Glairta S. Costa - Hospital Universitário Walter Cantídio, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

Jose Q.S. Filho - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-9619-4553

Alexandre Havt - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0002-4546-2976

Deiziane V.S. Costa - Infectious Diseases and International Health, University of Virginia, Charlottesvillle, VA 22908. https://orcid.org/0000-0001-6402-8908

Lyvia M.V.C. Magalhães - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil. https://orcid.org/0000-0001-6990-4903

Dilza Silva - Biomolecular Analysis Facility, School of Medicine, University of Virginia, Charlottesvillle, VA 22908. https://orcid.org/0000-0002-6519-346X

Nicholas E. Sherman - Biomolecular Analysis Facility, School of Medicine, University of Virginia, Charlottesvillle, VA 22908. https://orcid.org/0000-0003-3206-3113

Author Contributions:

- Bibliographic review and data collection, Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F Clementino and Aldo A.M. Lima.

- Methodology, Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F Clementino, Alexandre Havt, Ila F.N. Lima, Jorge L.N. Rodrigues, Luciana V. C. Fragoso and Aldo A. M. Lima.
- Bioinformatics, Lavouisier F.B. Nogueira and Marco A.F Clementino.
- In silico analyses, Lavouisier F.B. Nogueira, Marco A.F Clementino.
- *In vitro* validation of primers and sample testing, Lavouisier F.B. Nogueira, Marília S. Maia.
- Metabolomics, Datascience and data Bank, Jose Q.S. Filho; Deiziane V.S. Costa, José K. Sousa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman and Aldo A.M. Lima
- Written review and editing, Lavouisier F.B. Nogueira.
- Supervision, Alexandre Havt and Aldo A.M. Lima.
- Project administration, Aldo A.M. Lima.
- Resource acquisition, Aldo A.M. Lima.

Funding: This research was funded by CNPq (http://www.cnpq.br), grant numbers 402607/2018-0 and 408549/2022-0 and FUNCAP (https://www.funcap.ce.gov.br/), grant number: OFÍCIO Nº 102/2021 – DINOV.

Acknowledge: This work used the following equipments (Benchtop refrigerated centrifuge 10k RPM Eppendorf; Speed Vac Thermo fisher; Bead Ruptor Elite Omni International Material; Thermomixer Eppendorf; Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system) avaliable in the Biomolecular Analysis Core Facility which is supported by the University of Virginia School of Medicine, Research Resource Identifiers (RRID):SCR_025476.

Data Availability Statement: The data and reports relating to this study will be available via direct request via email to the corresponding author.

Conflicts of Interest: The authors declare that there are no financial or personal conflicts of interest that may have influenced the work.

REFERENCES

(1) Munita, J. M.; Arias, C. A. Mechanisms of Antibiotic Resistance. *Microbiol Spectr* **2016**, *4* (2). https://doi.org/10.1128/MICROBIOLSPEC.VMBF-0016-2015.

(2) Frieri, M.; Kumar, K.; Boutin, A. Antibiotic Resistance. *J Infect Public Health* **2017**, *10* (4), 369–378. https://doi.org/10.1016/J.JIPH.2016.08.007.

(3) Holt, K. E.; Wertheim, H.; Zadoks, R. N.; Baker, S.; Whitehouse, C. A.; Dance, D.; Jenney, A.; Connor, T. R.; Hsu, L. Y.; Severin, J.; Brisse, S.; Cao, H.; Wilksch, J.; Gorrie, C.; Schultz, M. B.; Edwards, D. J.; Van Nguyen, K.; Nguyen, T. V.; Dao, T. T.; Mensink, M.; Le Minh, V.; Nhu, N. T. K.; Schultsz, C.; Kuntaman, K.; Newton, P. N.; Moore, C. E.; Strugnell, R. A.; Thomson, N. R. Genomic Analysis of Diversity, Population Structure, Virulence, and Antimicrobial Resistance in Klebsiella Pneumoniae, an Urgent Threat to Public Health. *Proc Natl Acad Sci U S A* **2015**, *112* (27), E3574–E3581. https://doi.org/10.1073/PNAS.1501049112/SUPPL_FILE/PNAS.1501049112.SD01.XLSX.

(4) Asri, N. A. M.; Ahmad, S.; Mohamud, R.; Hanafi, N. M.; Zaidi, N. F. M.; Irekeola, A. A.; Shueb, R. H.; Yee, L. C.; Noor, N. M.; Mustafa, F. H.; Yean, C. Y.; Yusof, N. Y. Global Prevalence of Nosocomial Multidrug-Resistant Klebsiella Pneumoniae: A Systematic Review and Meta-Analysis. *Antibiotics* **2021**, *10* (12). https://doi.org/10.3390/ANTIBIOTICS10121508.

(5) Sharma, A.; Thakur, A.; Thakur, N.; Kumar, V.; Chauhan, A.; Bhardwaj, N. Changing Trend in the Antibiotic Resistance Pattern of Klebsiella Pneumonia Isolated From Endotracheal Aspirate Samples of ICU Patients of a Tertiary Care Hospital in North India. *Cureus* **2023**, *15* (3). https://doi.org/10.7759/CUREUS.36317.

(6) Cortés, G.; Borrell, N.; De Astorza, B.; Gómez, C.; Sauleda, J.; Albertí, S. Molecular Analysis of the Contribution of the Capsular Polysaccharide and the Lipopolysaccharide O Side Chain to the Virulence of Klebsiella Pneumoniae in a Murine Model of Pneumonia. *Infect Immun* **2002**, *70* (5), 2583–2590. https://doi.org/10.1128/IAI.70.5.2583-2590.2002/FORMAT/EPUB.

(7) Struve, C.; Bojer, M.; Krogfelt, K. A. Identification of a Conserved Chromosomal Region Encoding Klebsiella Pneumoniae Type 1 and Type 3 Fimbriae and Assessment of the Role of Fimbriae in Pathogenicity. *Infect Immun* **2009**, *77* (11), 5016–5024. https://doi.org/10.1128/IAI.00585-09/FORMAT/EPUB.

(8) Lin, C. T.; Chen, Y. C.; Jinn, T. R.; Wu, C. C.; Hong, Y. M.; Wu, W. H. Role of the CAMP-Dependent Carbon Catabolite Repression in Capsular Polysaccharide Biosynthesis in Klebsiella Pneumoniae. *PLoS One* **2013**, *8* (2), e54430. https://doi.org/10.1371/JOURNAL.PONE.0054430.

(9) Davies, J.; Davies, D. Origins and Evolution of Antibiotic Resistance. *Microbiol Mol Biol Rev* **2010**, *74* (3), 417. https://doi.org/10.1128/MMBR.00016-10.

(10) Salipante, S. J.; Jerome, K. R. Digital PCR-An Emerging Technology with Broad Applications in Microbiology. *Clin Chem* **2020**, *66* (1), 117–123. https://doi.org/10.1373/CLINCHEM.2019.304048.

(11) Fortuin, S.; Soares, N. C. The Integration of Proteomics and Metabolomics Data Paving the Way for a Better Understanding of the Mechanisms Underlying Microbial Acquired Drug Resistance. Frontiers in Medicine 2022, 9. https://doi.org/10.3389/fmed.2022.849838.

759 (12) Zeng, C.; Tandhanskul, A.; Krungkaew, S.; Likhanapaiboon, T.; Kasayapanan, W.;
760 Yasurin, P.; Tang, J.; Phusantisampan, T.; Tawai, A. Research Progress on Using Omics
761 Technology to Examine the Antimicrobial Mechanisms of Natural Active Substances.
762 Applied Science and Engineering Progress 2024.
763 https://doi.org/10.14416/j.asep.2024.07.003.
764 (13) Bush, K.; Bradford, P. A. β-Lactams and β-Lactamase Inhibitors: An Overview. *Cold*
765 *Spring Harb Perspect Med* **2016**, *6* (8). https://doi.org/10.1101/CSHPERSPECT.A025247.
766 (14) Ferreira, A. M.; Martins, K. B.; Silva, V. R. da; Mondelli, A. L.; Cunha, M. de L. R. de S. da.
767 Correlation of Phenotypic Tests with the Presence of the BlaZ Gene for Detection of Beta-
768 Lactamase. *Braz J Microbiol* **2017**, *48* (1), 159–166.
769 https://doi.org/10.1016/J.BJM.2016.10.011.
770 (15) Zhu, L. J.; Pan, Y.; Gao, C. Y.; Hou, P. F. Distribution of Carbapenemases and Efflux
771 Pump in Carbapenem-Resistance Acinetobacter Baumannii. *Ann Clin Lab Sci* **2020**, *50* (2).
772 (16) Makharita, R. R.; El-Kholy, I.; Hetta, H. F.; Abdelaziz, M. H.; Hagagy, F. I.; Ahmed, A. A.;
773 Algammal, A. M. Antibiogram and Genetic Characterization of Carbapenem-Resistant
774 Gram-Negative Pathogens Incriminated in Healthcare-Associated Infections. *Infect Drug*
775 *Resist* **2020**, *13*, 3991–4002. https://doi.org/10.2147/IDR.S276975.
776 (17) Santos, A. L.; Dos Santos, A. P.; Ito, C. R. M.; de Queiroz, P. H. P.; de Almeida, J. A.;
777 Júnior, M. A. B. de C.; de Oliveira, C. Z.; Avelino, M. A. G.; Wastowski, I. J.; Gomes, G. P.
778 L. A.; E Souza, A. C. S.; Vasconcelos, L. S. N. de O. L.; Santos, M. de O.; da Silva, C. A.;
779 Carneiro, L. C. Profile of Enterobacteria Resistant to Beta-Lactams. *Antibiotics* **2020**, *9* (7),
780 1–18. https://doi.org/10.3390/ANTIBIOTICS9070410.
781 (18) Abdel-Rhman, S. H. Characterization of β-Lactam Resistance in K. Pneumoniae
782 Associated with Ready-to-Eat Processed Meat in Egypt. *PLoS One* **2020**, *15* (9), e0238747.
783 https://doi.org/10.1371/JOURNAL.PONE.0238747.

(19) Messaoudi, A.; Mansour, W.; Jaidane, N.; Chaouch, C.; Boujaâfar, N.; Bouallègue, O. Epidemiology of Resistance and Phenotypic Characterization of Carbapenem Resistance Mechanisms in Klebsiella Pneumoniae Isolates at Sahloul University Hospital-Sousse, Tunisia. *Afr Health Sci* **2019**, *19* (2), 2008–2020. https://doi.org/10.4314/AHS.V19I2.24.

(20) Farhadi, M.; Ahanjan, M.; Goli, H. R.; Haghshenas, M. R.; Gholami, M. High Frequency of Multidrug-Resistant (MDR) Klebsiella Pneumoniae Harboring Several β-Lactamase and Integron Genes Collected from Several Hospitals in the North of Iran. *Annals of Clinical Microbiology and Antimicrobials* **2021**, *20* (1). https://doi.org/10.1186/s12941-021-00476-1.

(21) Oliveira, R.; Castro, J.; Silva, S.; Oliveira, H.; Saavedra, M. J.; Azevedo, N. F.; Almeida, C. Exploring the Antibiotic Resistance Profile of Clinical Klebsiella Pneumoniae Isolates in Portugal. *Antibiotics (Basel)* **2022**, *11* (11). https://doi.org/10.3390/ANTIBIOTICS11111613.

(22) Bush, K.; Bradford, P. A. Epidemiology of β-Lactamase-Producing Pathogens. *Clin Microbiol Rev* **2020**, *33* (2). https://doi.org/10.1128/CMR.00047-19.

(23) Castanheira, M.; Simner, P. J.; Bradford, P. A. Extended-Spectrum β-Lactamases: An Update on Their Characteristics, Epidemiology and Detection. *JAC Antimicrob Resist* **2021**, *3* (3). https://doi.org/10.1093/JACAMR/DLAB092.

(24) Gundran, R. S.; Cardenio, P. A.; Villanueva, M. A.; Sison, F. B.; Benigno, C. C.; Kreausukon, K.; Pichpol, D.; Punyapornwithaya, V. Prevalence and Distribution of BlaCTX-M, BlaSHV, BlaTEM Genes in Extended- Spectrum β- Lactamase- Producing E. Coli Isolates from Broiler Farms in the Philippines. *BMC Vet Res* **2019**, *15* (1). https://doi.org/10.1186/S12917-019-1975-9.

(25) Queiroz, J. A. da S.; Alves, L. S.; Dall'acqua, D. S. V.; Souza, L. F. B.; Faculdades Integradas Aparício Carvalho. Porto Velho, R. Brasil.; Faculdades Integradas Aparício Carvalho. Porto Velho, R. Brasil.; Fundação Oswaldo Cruz. Porto Velho, R. Brasil. / F. I. A. Carvalho. P. V. R. Brasil.; Faculdades Integradas Aparício Carvalho. Porto Velho, R.

809 Brasil. Desenho e Validação de Primers In Silico Para Detecção Do Vírus Sincicial
810 Respiratório Humano. *Revista FIMCA* **2017**, *4* (1), 17–30.
811 (26) Kumar, A.; Chordia, N. In Silico PCR Primer Designing and Validation. *Methods Mol Biol*
812 **2015**, *1275*, 143–151. https://doi.org/10.1007/978-1-4939-2365-6_10.
813 (27) Rodríguez, A.; Rodríguez, M.; Córdoba, J. J.; Andrade, M. J. Design of Primers and Probes
814 for Quantitative Real-Time PCR Methods. *Methods in Molecular Biology* **2015**, *1275*, 31–56.
815 https://doi.org/10.1007/978-1-4939-2365-6_3.
816 (28) van Weezep, E.; Kooi, E. A.; van Rijn, P. A. PCR Diagnostics: In Silico Validation by an
817 Automated Tool Using Freely Available Software Programs. *J Virol Methods* **2019**, *270*,
818 106–112. https://doi.org/10.1016/J.JVIROMET.2019.05.002.
819 (29) Yang, J.; Kemps-Mols, B.; Spruyt-Gerritse, M.; Anholts, J.; Claas, F.; Eikmans, M. The
820 Source of SYBR Green Master Mix Determines Outcome of Nucleic Acid Amplification
821 Reactions. *BMC Res Notes* **2016**, *9* (1), 1–10. https://doi.org/10.1186/S13104-016-2093-
822 4/FIGURES/4.
823 (30) Wang, Y.; Li, W.; Guo, X.; Zhang, D.; Sun, J.; Fu, Z.; Liu, G.; Li, Y.; Jiang, S. Development
824 of SYBR Green I-Based Polymerase Chain Reaction for Feline Bocavirus 1 Detection. *3*
825 *Biotech* **2021**, *11* (2). https://doi.org/10.1007/S13205-020-02577-8.
826 (31) Desriani; Azamris; Ghaissani, S. S.; Kinanti, S. R.; Warisman, M. A.; Fitria, N. Design and
827 Characterization of a SYBR Green I-Based Melting Curve Method for Investigation of
828 HER2I655V Polymorphism in Breast Cancer. *J Genet Eng Biotechnol* **2021**, *19* (1).
829 https://doi.org/10.1186/S43141-020-00108-9.
830 (32) Svec, D.; Tichopad, A.; Novosadova, V.; Pfaffl, M. W.; Kubista, M. How Good Is a PCR
831 Efficiency Estimate: Recommendations for Precise and Robust QPCR Efficiency
832 Assessments. *Biomol Detect Quantif* **2015**, *3*, 9–16.
833 https://doi.org/10.1016/J.BDQ.2015.01.005.

834 (33) Thermo Fisher Scientific. *Real-Time PCR: Understanding Ct - US*.
835 https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-pcr/real-time-pcr-
836 learning-center/real-time-pcr-basics/real-time-pcr-understanding-ct.html (accessed 2024-
837 05-05).
838 (34) Han, R.; Shi, Q.; Wu, S.; Yin, D.; Peng, M.; Dong, D.; Zheng, Y.; Guo, Y.; Zhang, R.; Hu, F.
839 Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among
840 Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in
841 China. *Front Cell Infect Microbiol* **2020**, *10*, 314. https://doi.org/10.3389/FCIMB.2020.00314.
842 (35) Marschall, J.; Tibbetts, R. J.; Dunne, W. M.; Frye, J. G.; Fraser, V. J.; Warren, D. K. Presence
843 of the KPC Carbapenemase Gene in Enterobacteriaceae Causing Bacteremia and Its
844 Correlation with In Vitro Carbapenem Susceptibility. *J Clin Microbiol* **2009**, *47* (1), 239.
845 https://doi.org/10.1128/JCM.02123-08.
846 (36) Kharazmkia, A.; Amirizadeh, M.; Goudarzi, Z.; Birjandi, M.; Barfipoursalar, A.; Mir, S.
847 Prevalence of KPC-Producing Bacteria in Negative Gram of Clinical Samples Obtained
848 from Patients. *Annals of Medicine and Surgery* **2022**, *77*, 103690.
849 https://doi.org/10.1016/J.AMSU.2022.103690.
850 (37) Pawłowska, I.; Ziółkowski, G.; Jachowicz-Matczak, E.; Stasiowski, M.; Gajda, M.;
851 Wójkowska-Mach, J. Colonization and Healthcare-Associated Infection of Carbapenem-
852 Resistant Enterobacteriaceae, Data from Polish Hospital with High Incidence of
853 Carbapenem-Resistant Enterobacteriaceae, Does Active Target Screening Matter?
854 *Microorganisms* **2023**, *11* (2). https://doi.org/10.3390/MICROORGANISMS11020437.
855 (38) Ferreira, R. L.; da Silva, B. C. M.; Rezende, G. S.; Nakamura-Silva, R.; Pitondo-Silva, A.;
856 Campanini, E. B.; Brito, M. C. A.; da Silva, E. M. L.; Freire, C. C. de M.; Cunha, A. F. da;
857 Pranchevicius, M.-C. da S. High Prevalence of Multidrug-Resistant Klebsiella
858 Pneumoniae Harboring Several Virulence and β-Lactamase Encoding Genes in a

859 Brazilian Intensive Care Unit. *Frontiers in Microbiology* **2019**, *9*.
860 https://doi.org/10.3389/fmicb.2018.03198.
861 (39) Kernéis, S.; Lucet, J. C.; Santoro, A.; Meschiari, M. Individual and Collective Impact of
862 Klebsiella Pneumoniae Carbapenemase (KPC)-Producing K. Pneumoniae in Patients
863 Admitted to the ICU. *J Antimicrob Chemother* **2021**, *76* (Suppl 1), I19–I26.
864 https://doi.org/10.1093/JAC/DKAA494.
865 (40) Dirar, M. H.; Bilal, N. E.; Ibrahim, M. E.; Hamid, M. E. Prevalence of Extended-Spectrum
866 β-Lactamase (ESBL) and Molecular Detection of Bla TEM, Bla SHV and Bla CTX-M
867 Genotypes among Enterobacteriaceae Isolates from Patients in Khartoum, Sudan. *Pan Afr*
868 *Med J* **2020**, *37*, 1–11. https://doi.org/10.11604/PAMJ.2020.37.213.24988.
869 (41) Pavez, M.; Troncoso, C.; Osses, I.; Salazar, R.; Illesca, V.; Reydet, P.; Rodríguez, C.;
870 Chahin, C.; Concha, C.; Barrientos, L. High Prevalence of CTX-M-1 Group in ESBL-
871 Producing Enterobacteriaceae Infection in Intensive Care Units in Southern Chile. *Braz J*
872 *Infect Dis* **2019**, *23* (2), 102–110. https://doi.org/10.1016/J.BJID.2019.03.002.
873 (42) Camargo, C. H.; Yamada, A. Y.; Souza, A. R. de; Reis, A. D.; Santos, M. B. N.; Assis, D. B.
874 de; Carvalho, E. de; Takagi, E. H.; Cunha, M. P. V.; Tiba-Casas, M. R. Genomic Diversity
875 of NDM-Producing Klebsiella Species from Brazil, 2013–2022. Antibiotics 2022, 11 (10),
876 1395.https://doi.org/10.3390/antibiotics11101395.
877 (43) Vivas, R.; Dolabella, S. S.; Barbosa, A. A. T.; Jain, S. Prevalence of Klebsiella Pneumoniae
878 Carbapenemase - and New Delhi Metallo-Beta-Lactamase-Positive K. Pneumoniae in
879 Sergipe, Brazil, and Combination Therapy as a Potential Treatment Option. *Revista da*
880 *Sociedade Brasileira de Medicina Tropical* **2020**, *53*. https://doi.org/10.1590/0037-8682-0064-
881 2020.
882 (44) Belouad, E. M.; Benaissa, E.; El Mrimar, N.; Bssaibis, F.; Maleb, A.; Elouennass, M.
883 Predominance of OXA-48 Carbapenemase-Producing Enterobacterales in a Moroccan
884 Hospital. *Int J Microbiol* **2023**, *2023*. https://doi.org/10.1155/2023/8581883.

885 (45) Magagnin, C. M.; Rozales, F. P.; Antochevis, L.; Nunes, L. S.; Martins, A. S.; Barth, A. L.;
886 Sampaio, J. M.; Zavascki, A. P. Dissemination of Bla OXA-370 Gene among Several
887 Enterobacteriaceae Species in Brazil. *Eur J Clin Microbiol Infect Dis* **2017**, *36* (10), 1907–
888 1910. https://doi.org/10.1007/S10096-017-3012-X.
889 (46) Evans, B. A.; Amyes, S. G. B. OXA β-Lactamases. *Clin Microbiol Rev* **2014**, *27* (2), 241–263.
890 https://doi.org/10.1128/CMR.00117-13/ASSET/DF7BB1F6-F6E8-4208-8829-
891 B01CD28A0242/ASSETS/GRAPHIC/ZCM9990924610006.JPEG.
892 (47) Shahid, M.; Ahmad, N.; Saeed, N. K.; Shadab, M.; Joji, R. M.; Al-Mahmeed, A.; Bindayna,
893 K. M.; Tabbara, K. S.; Dar, F. K. Clinical Carbapenem-Resistant Klebsiella Pneumoniae
894 Isolates Simultaneously Harboring Bla NDM-1, Bla OXA Types and QnrS Genes from the
895 Kingdom of Bahrain: Resistance Profile and Genetic Environment. *Front Cell Infect*
896 *Microbiol* **2022**, *12*. https://doi.org/10.3389/FCIMB.2022.1033305.
897 (48) Manandhar, S.; Zellweger, R. M.; Maharjan, N.; Dongol, S.; Prajapati, K. G.; Thwaites, G.;
898 Basnyat, B.; Dixit, S. M.; Baker, S.; Karkey, A. A High Prevalence of Multi-Drug Resistant
899 Gram-Negative Bacilli in a Nepali Tertiary Care Hospital and Associated Widespread
900 Distribution of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-
901 Encoding Genes. *Ann Clin Microbiol Antimicrob* **2020**, *19* (1), 1–13.
902 https://doi.org/10.1186/S12941-020-00390-Y/FIGURES/5.
903 (49) Awosile, B. B.; Agbaje, M.; Adebowale, O.; Kehinde, O.; Omoshaba, E. Beta-Lactamase
904 Resistance Genes in Enterobacteriaceae from Nigeria. *Afr J Lab Med* **2022**, *11* (1).
905 https://doi.org/10.4102/AJLM.V11I1.1371.
906 (50) Han, M. L.; Nang, S. C.; Lin, Y. W.; Zhu, Y.; Yu, H. H.; Wickremasinghe, H.; Barlow, C. K.;
907 Creek, D. J.; Crawford, S.; Rao, G.; Dai, C.; Barr, J. J.; Chan, K.; Turner Schooley, R.;
908 Velkov, T.; Li, J. Comparative Metabolomics Revealed Key Pathways Associated with the
909 Synergistic Killing of Multidrug-Resistant Klebsiella Pneumoniae by a Bacteriophage-

910 Polymyxin Combination. *Comput Struct Biotechnol J* **2022**, *20*, 485–495.
911 https://doi.org/10.1016/J.CSBJ.2021.12.039.
912 (51) Kumar, A.; Singh, S.; Gupta, S. K.; Kumar, S.; Kumar, S.; Singh, R.; Thakur, L.; Kumar, M.;
913 Kapil, A.; Kumar, Y.; Kumar, N. Identification of Metabolite Extraction Method for
914 Targeted Exploration of Antimicrobial Resistance Associated Metabolites of Klebsiella
915 Pneumoniae. *Sci Rep* **2022**, *12* (1). https://doi.org/10.1038/S41598-022-12153-0.
916 (52) Hudson, A. W.; Barnes, A. J.; Bray, A. S.; Ornelles, D. A.; Zafar, M. A. Klebsiella
917 Pneumoniae L-Fucose Metabolism Promotes Gastrointestinal Colonization and
918 Modulates Its Virulence Determinants. *Infect Immun* **2022**, *90* (10).
919 https://doi.org/10.1128/IAI.00206-22.
920 (53) Lin, D.; Fan, J. M.; Wang, J.; Liu, L.; Xu, L.; Li, F.; Yang, J.; Li, B. The Fructose-Specific
921 Phosphotransferase System of Klebsiella Pneumoniae Is Regulated by Global Regulator
922 CRP and Linked to Virulence and Growth. *Infect Immun* **2018**, *86* (8).
923 https://doi.org/10.1128/IAI.00340-18.
924 (54) Aminov, R. Metabolomics in Antimicrobial Drug Discovery. *Expert Opinion on Drug*
925 *Discovery* **2022**, *17* (9), 1047–1059. https://doi.org/10.1080/17460441.2022.2113774.
926 (55) Kok, M.; Maton, L.; van der Peet, M.; Hankemeier, T.; van Hasselt, J. G. C. Unraveling
927 Antimicrobial Resistance Using Metabolomics. *Drug Discovery Today* **2022**, *27* (6), 1774–
928 1783. https://doi.org/10.1016/j.drudis.2022.03.015.
929 (56) Soni, V.; Wang, Z.; Singh, V. Editorial: Bacterial Metabolomics Approach towards
930 Antimicrobials and Resistance. *Frontiers in Microbiology* **2023**, *14*.
931 https://doi.org/10.3389/fmicb.2023.1222594.
932 (57) Abril, A. G.; Quintela-Baluja, M.; Villa, T. G.; Calo-Mata, P.; Barros-Velázquez, J.; Carrera,
933 M. Proteomic Characterization of Virulence Factors and Related Proteins in Enterococcus
934 Strains from Dairy and Fermented Food Products. International Journal of Molecular
935 Sciences 2022, 23 (18), 10971. https://doi.org/10.3390/ijms231810971.

(58) Azhar, F.; Busharat, M.; Chaudhary, S. R.; Waheed, Z.; Jamil, M. Metabolomics in Drug Discovery: Restoring Antibiotic Pipeline. *Asian Pacific Journal of Tropical Biomedicine* **2023**, *13* (9), 378. https://doi.org/10.4103/2221-1691.385568.

(59) Tsugawa, H.; Cajka, T.; Kind, T.; Ma, Y.; Higgins, B.; Ikeda, K.; Kanazawa, M.; Vandergheynst, J.; Fiehn, O.; Arita, M. MS-DIAL: Data-Independent MS/MS Deconvolution for Comprehensive Metabolome Analysis. *Nature Methods 2015 12:6* **2015**, *12* (6), 523–526. https://doi.org/10.1038/nmeth.3393.

(60) Tsugawa, H.; Nakabayashi, R.; Mori, T.; Yamada, Y.; Takahashi, M.; Rai, A.; Sugiyama, R.; Yamamoto, H.; Nakaya, T.; Yamazaki, M.; Kooke, R.; Bac-Molenaar, J. A.; Oztolan-Erol, N.; Keurentjes, J. J. B.; Arita, M.; Saito, K. A Cheminformatics Approach to Characterize Metabolomes in Stable-Isotope-Labeled Organisms. *Nat Methods* **2019**, *16* (4), 295–298. https://doi.org/10.1038/S41592-019-0358-2.